DRI Capital is a private equity general partner firm headquartered in Toronto, ON, Canada.
DRI Capital acquired a portion of the Institute of Cancer Research's royalty entitlement relating to sales of the cancer drug Zytiga.
DRI Capital has bought the rights to a certain drug from Rush University Medical Center with about $42m from its Drug Royalty III fund.
Read more news concerning DRI Capital
A sampling of DRI Capital portfolio companies:
View all of the investments in their portfolio
Registration is fast, free and easy
Already a member?